PMID- 11790166
OWN - NLM
STAT- MEDLINE
DCOM- 20020205
LR  - 20220330
IS  - 0003-987X (Print)
IS  - 0003-987X (Linking)
VI  - 138
IP  - 1
DP  - 2002 Jan
TI  - Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell 
      lymphomas: the severity-weighted assessment tool (SWAT).
PG  - 42-8
AB  - OBJECTIVE: To develop a quantitative tool to assess severity of mycosis 
      fungoides. DESIGN: Prospective analysis of a cohort. SETTING: University 
      department of dermatology-based cutaneous lymphoma clinic. PATIENTS: From 1984 to 
      1995, 1186 visits from 323 referred patients seen in a multidisciplinary 
      cutaneous lymphoma program. MAIN OUTCOME MEASURES: Severity-weighted assessment 
      tool (SWAT) scores were obtained for patients at each visit. This score 
      represents the product of the percentage total body surface area (%TBSA) 
      involvement of each lesion type (patch, plaque, and tumor or ulceration), 
      multiplied by a weighting factor: SWAT = (patch %TBSA x 1) + (plaque %TBSA x 2) + 
      (tumor or ulcer %TBSA x 3). In addition, the standard measurements of TBSA 
      involvement and physician global assessments were recorded for comparison. 
      RESULTS: The SWAT score correlated well with %TBSA (r = 0.95, P<.001), physician 
      global assessment (r = 0.60, P<.001), and time to complete remission during 
      psoralen-UV-A therapy (r = 0.80, P<.001), therefore indicating validity against 
      standard measures. Analysis of individual and subsets of patients demonstrated 
      that the SWAT score more accurately quantified changes in skin disease burden, 
      including mixed responses to treatment, than did %TBSA alone. CONCLUSIONS: The 
      SWAT score is a useful clinical measurement for mycosis fungoides. The SWAT score 
      captures overall physician impressions of disease status on a continuous 
      dimensionless numerical scale, therefore providing a defined, objective, and 
      sensitive quantitative measure. This tool is suitable for individual patient 
      assessment, clinical trials, and outcome comparisons.
FAU - Stevens, Seth R
AU  - Stevens SR
AD  - Department of Dermatology, University Hospitals of Cleveland, Case Western 
      Reserve University, 11100 Euclid Ave, Cleveland, OH 44106-5028, USA. 
      srs@po.cwru.edu
FAU - Ke, Malcolm S
AU  - Ke MS
FAU - Parry, Eileen J
AU  - Parry EJ
FAU - Mark, Julie
AU  - Mark J
FAU - Cooper, Kevin D
AU  - Cooper KD
LA  - eng
GR  - 1KO8ARO2063/AR/NIAMS NIH HHS/United States
GR  - 5P30AR39750/AR/NIAMS NIH HHS/United States
GR  - P30CA43703/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Arch Dermatol
JT  - Archives of dermatology
JID - 0372433
SB  - IM
MH  - Cohort Studies
MH  - Confidence Intervals
MH  - Female
MH  - Humans
MH  - Male
MH  - Mycosis Fungoides/diagnosis/*pathology/therapy
MH  - Neoplasm Staging
MH  - Probability
MH  - Prospective Studies
MH  - Registries
MH  - Sensitivity and Specificity
MH  - *Severity of Illness Index
MH  - *Sick Role
MH  - Skin Neoplasms/diagnosis/*pathology/therapy
EDAT- 2002/01/16 10:00
MHDA- 2002/02/06 10:01
CRDT- 2002/01/16 10:00
PHST- 2002/01/16 10:00 [pubmed]
PHST- 2002/02/06 10:01 [medline]
PHST- 2002/01/16 10:00 [entrez]
AID - dst00160 [pii]
AID - 10.1001/archderm.138.1.42 [doi]
PST - ppublish
SO  - Arch Dermatol. 2002 Jan;138(1):42-8. doi: 10.1001/archderm.138.1.42.